In this study, we confirmed the pro-oncogenic effects of EDA+FN, and the EDA exon-eliminating CRISPR/Cas9 plasmids were used both in vitro and in vivo to inhibit various tumor progression, based on our previous study [15]. Here, FN1 is linked to neoplasm.